Forte Biosciences Inc
FBRX13.510USD
+0.300+2.27%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
165.93MMarket Cap
LossP/E TTM
More Details of Forte Biosciences Inc Company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Company Info
Ticker SymbolFBRX
Company nameForte Biosciences Inc
IPO dateApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 13
Address3060 Pegasus Park Drive
CityDALLAS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code75247
Phone13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
Ticker SymbolFBRX
IPO dateApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fred Alger Management, LLC
13.02%
Federated Hermes Global Investment Management Corp.
11.89%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Other
47.91%
Shareholders
Shareholders
Proportion
Fred Alger Management, LLC
13.02%
Federated Hermes Global Investment Management Corp.
11.89%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Other
47.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.33%
Hedge Fund
25.35%
Private Equity
10.18%
Investment Advisor
5.53%
Corporation
3.95%
Individual Investor
1.01%
Research Firm
0.08%
Other
9.58%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
80
7.19M
109.15%
+1.76M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
2023Q1
185
468.85K
56.07%
-1.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fred Alger Management, LLC
910.61K
13.83%
-223.34K
-19.70%
Mar 31, 2025
Janus Henderson Investors
920.00K
13.97%
+229.26K
+33.19%
Mar 31, 2025
OrbiMed Advisors, LLC
593.09K
9.01%
-6.91K
-1.15%
Mar 31, 2025
Tybourne Capital Management (HK) Limited
619.98K
9.42%
--
--
Mar 31, 2025
BVF Partners L.P.
594.28K
9.03%
--
--
Mar 31, 2025
Cable Car Capital LLC
219.60K
3.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
88.95K
1.35%
+62.56K
+237.01%
Mar 31, 2025
Ikarian Capital LLC
609.23K
9.25%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Date
Type
Ratio
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
